Synthesis and antimicrobial testing of 5-fluorouracil derivatives. 2023

Mrunal Patil, and Krykun Serhii, and Frédéric Garzino, and Quentin Gobert, and Suzanne Giorgio, and Jean-Manuel Raimundo, and Jean-Michel Bolla, and Michel Camplo
Aix Marseille Université, INSERM, SSA, MCT, Marseille, France.

Antibiotic resistance has increased the demand for novel treatments against multidrug-resistant microorganisms. In the research literature, 5-fluorouracil (5-FU) was proposed as an alternative due to its intrinsic antibacterial property. However, given its toxicity profile at high doses, its use in antibacterial therapy is dubious. In the quest for improving the efficacy of 5-FU, the present study intends to synthesise 5-FU derivatives and assess their susceptibility and mechanism against pathogenic bacteria. It was found that the compounds having tri-hexylphosphonium substitution on both nitrogen groups of 5-FU (6a, 6b and 6c) had considerable activity against both Gram-positive and Gram-negative bacteria. Among the active compounds, those with an asymmetric linker group 6c were found to have higher antibacterial efficacy. However, no conclusive efflux inhibition activity was found. As elucidated by electron microscopy studies, these self-assembling active phosphonium-based 5-FU derivatives caused considerable septal damage and cytosolic alterations in Staphylococcus aureus cells. In Escherichia coli, these compounds triggered plasmolysis. Interestingly, the minimal inhibitory concentration (MIC) of the most potent 5-FU derivative 6c remained constant, regardless of the bacteria's resistance profile. Further analysis revealed that compound 6c generated significant alterations in membrane permeabilization and depolarization in S. aureus and E. coli cells at the MIC. Compound 6c was found to substantially impede bacterial motility, suggesting its importance in regulating bacterial pathogenicity. Additionally, the nonhaemolytic activity of 6c suggested that it could be a potential therapeutic option for treating multidrug-resistant bacterial infections.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D004926 Escherichia coli A species of gram-negative, facultatively anaerobic, rod-shaped bacteria (GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS) commonly found in the lower part of the intestine of warm-blooded animals. It is usually nonpathogenic, but some strains are known to produce DIARRHEA and pyogenic infections. Pathogenic strains (virotypes) are classified by their specific pathogenic mechanisms such as toxins (ENTEROTOXIGENIC ESCHERICHIA COLI), etc. Alkalescens-Dispar Group,Bacillus coli,Bacterium coli,Bacterium coli commune,Diffusely Adherent Escherichia coli,E coli,EAggEC,Enteroaggregative Escherichia coli,Enterococcus coli,Diffusely Adherent E. coli,Enteroaggregative E. coli,Enteroinvasive E. coli,Enteroinvasive Escherichia coli
D006090 Gram-Negative Bacteria Bacteria which lose crystal violet stain but are stained pink when treated by Gram's method. Gram Negative Bacteria
D006094 Gram-Positive Bacteria Bacteria which retain the crystal violet stain when treated by Gram's method. Gram Positive Bacteria
D000890 Anti-Infective Agents Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. Anti-Infective Agent,Anti-Microbial Agent,Antimicrobial Agent,Microbicide,Microbicides,Anti-Microbial Agents,Antiinfective Agents,Antimicrobial Agents,Agent, Anti-Infective,Agent, Anti-Microbial,Agent, Antimicrobial,Agents, Anti-Infective,Agents, Anti-Microbial,Agents, Antiinfective,Agents, Antimicrobial,Anti Infective Agent,Anti Infective Agents,Anti Microbial Agent,Anti Microbial Agents
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D001419 Bacteria One of the three domains of life (the others being Eukarya and ARCHAEA), also called Eubacteria. They are unicellular prokaryotic microorganisms which generally possess rigid cell walls, multiply by cell division, and exhibit three principal forms: round or coccal, rodlike or bacillary, and spiral or spirochetal. Bacteria can be classified by their response to OXYGEN: aerobic, anaerobic, or facultatively anaerobic; by the mode by which they obtain their energy: chemotrophy (via chemical reaction) or PHOTOTROPHY (via light reaction); for chemotrophs by their source of chemical energy: CHEMOLITHOTROPHY (from inorganic compounds) or chemoorganotrophy (from organic compounds); and by their source for CARBON; NITROGEN; etc.; HETEROTROPHY (from organic sources) or AUTOTROPHY (from CARBON DIOXIDE). They can also be classified by whether or not they stain (based on the structure of their CELL WALLS) with CRYSTAL VIOLET dye: gram-negative or gram-positive. Eubacteria
D013211 Staphylococcus aureus Potentially pathogenic bacteria found in nasal membranes, skin, hair follicles, and perineum of warm-blooded animals. They may cause a wide range of infections and intoxications.
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

Mrunal Patil, and Krykun Serhii, and Frédéric Garzino, and Quentin Gobert, and Suzanne Giorgio, and Jean-Manuel Raimundo, and Jean-Michel Bolla, and Michel Camplo
November 2007, Molecules (Basel, Switzerland),
Mrunal Patil, and Krykun Serhii, and Frédéric Garzino, and Quentin Gobert, and Suzanne Giorgio, and Jean-Manuel Raimundo, and Jean-Michel Bolla, and Michel Camplo
January 2013, Bioorganicheskaia khimiia,
Mrunal Patil, and Krykun Serhii, and Frédéric Garzino, and Quentin Gobert, and Suzanne Giorgio, and Jean-Manuel Raimundo, and Jean-Michel Bolla, and Michel Camplo
August 1985, Chemical & pharmaceutical bulletin,
Mrunal Patil, and Krykun Serhii, and Frédéric Garzino, and Quentin Gobert, and Suzanne Giorgio, and Jean-Manuel Raimundo, and Jean-Michel Bolla, and Michel Camplo
January 1996, Medicinal research reviews,
Mrunal Patil, and Krykun Serhii, and Frédéric Garzino, and Quentin Gobert, and Suzanne Giorgio, and Jean-Manuel Raimundo, and Jean-Michel Bolla, and Michel Camplo
May 2002, Journal of controlled release : official journal of the Controlled Release Society,
Mrunal Patil, and Krykun Serhii, and Frédéric Garzino, and Quentin Gobert, and Suzanne Giorgio, and Jean-Manuel Raimundo, and Jean-Michel Bolla, and Michel Camplo
July 2004, Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition,
Mrunal Patil, and Krykun Serhii, and Frédéric Garzino, and Quentin Gobert, and Suzanne Giorgio, and Jean-Manuel Raimundo, and Jean-Michel Bolla, and Michel Camplo
July 2006, Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition,
Mrunal Patil, and Krykun Serhii, and Frédéric Garzino, and Quentin Gobert, and Suzanne Giorgio, and Jean-Manuel Raimundo, and Jean-Michel Bolla, and Michel Camplo
October 1997, Die Pharmazie,
Mrunal Patil, and Krykun Serhii, and Frédéric Garzino, and Quentin Gobert, and Suzanne Giorgio, and Jean-Manuel Raimundo, and Jean-Michel Bolla, and Michel Camplo
January 2009, Indian journal of pharmaceutical sciences,
Mrunal Patil, and Krykun Serhii, and Frédéric Garzino, and Quentin Gobert, and Suzanne Giorgio, and Jean-Manuel Raimundo, and Jean-Michel Bolla, and Michel Camplo
May 1998, Yao xue xue bao = Acta pharmaceutica Sinica,
Copied contents to your clipboard!